Osteonecrosis Treatment Market Increase in research activities for new vaccines by manufacturers is expected to boost the growth of the market

𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐬𝐭𝐞𝐨𝐧𝐞𝐜𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

Osteonecrosis is a disease in which the bone cells collapse due to lack of blood flow in the bones. It is also known as avascular necrosis, aseptic necrosis or ischemic necrosis. Osteonecrosis is most commonly developed in hip bone (femur) or knees, while less often in shoulder, wrist, ankle, hands, and feet. It can cause mild to severe pain and may lead to micro-fracture. Osteonecrosis can be diagnosed by using X-ray, CT scan, MRI, bone scan, and functional bone tests. Osteonecrosis treatment targets symptoms and reduces pain via medication or surgery in extreme cases. According to the National Organization for Rare Disorders, osteonecrosis is one of the rare diseases, where less than 1 in 2000 are only affected by this disorder. In 2017, Bone Therapeutics reported that around 170,000 patients were suffering from osteonecrosis in Europe, the U.S., and Japan. The advancements in treatment technologies and gene therapy and stem cell-based osteonecrosis treatment are expected to propel growth of the global osteonecrosis treatment market during the forecast period.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/request-sample/1490

𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐬𝐭𝐞𝐨𝐧𝐞𝐜𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤

Advanced Therapy Medicinal Products (ATMPs) are a class of innovative therapies that comprise gene therapy, somatic cell therapy, and tissue-engineered products, and their introduction into the market is expected to drive the global osteonecrosis treatment market development. Osteonecrosis usually affects young population and this significantly will contributes towards growth of osteonecrosis treatment market. For instance, according to the American College of Rheumatology, in 2017, around 10,000 to 20,000 people in the U.S. who suffered from osteonecrosis were between the ages of 20 and 50. Currently, the osteonecrosis non-surgical treatment (medication) is symptomatic treatment that targets the symptoms and try to cure the disease. Hence, emerging players in the field of bone disease treatment is gaining momentum by introducing gene regulation approach. The key market players like Enzo Biochem, Inc. and Bone Therapeutics are aiming gene regulation and cell-based product treatment, which is expected to augment growth of osteonecrosis treatment market. For instance, PREOB manufactured by Bone Therapeutics, a cell-based medicinal product derived from autologous bone marrow stem cells, has been approved in the U.S., and is currently in the third phase of development in Europe.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐇𝐞𝐫𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/1490

Although osteonecrosis is a rare disease, the global osteonecrosis treatment market is expected to grow tremendously, due to the burgeoning prevalence of causative agents for osteonecrosis. Side effects of various medicines taken during cancer, HIV/AIDS, osteoarthritis, osteoporosis or blood disorders or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids or organ transplants may increases the chances of having osteonecrosis. Furthermore, a few interventions such as Stanford University’s sponsored project aims at evaluation of osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI, which improve detection and allow to track transplanted bone marrow cells. This intervention is in phase IV clinical trial and is expected to complete the project over the forecast period, which in turn, would propel the growth of the global osteonecrosis treatment market.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

North America is expected to hold a dominant position in the global osteonecrosis treatment market over the forecast period, due to increasing prevalence pool of osteonecrosis, and FDA approvals for new treatment options in the region. According to the 2015 NCBI report, it is estimated that around 20,000 to 30,000 new patients are diagnosed with osteonecrosis in the U.S. annually. Furthermore, the Asia Pacific market is expected to grow at a comparatively faster rate in the global osteonecrosis treatment market over the forecast period, owing to the increasing developmental activities carried out by various key players in this region. For instance, Bone Therapeutics and Asahi Kasei Corporation signed a license agreement in 2017 for the development and commercialization of PREOB in Japan.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐬𝐭𝐞𝐨𝐧𝐞𝐜𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 – 𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫𝐬

The major players involved in the global osteonecrosis treatment market include Bone Therapeutics, Enzo Biochem Inc., K-Stemcell Co. Ltd. Hospitals, and numerous leading universities and institutes.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 – https://www.coherentmarketinsights.com/insight/buy-now/1490

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐒:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.